⚠ Tool for educational and informational purposes only — not investment advice or a recommendation to buy or sell. Investing carries risk of capital loss. Read the full disclaimer.
IBRX — ImmunityBio, Inc.
Last scan (Sept. 18, 2026): price $8.46, RSI 57.37, relative volume 2.23x, MACD 🟢 Yes, score 73.71.
It's in a bullish underlying trend (above its 200-day average), with an RSI of 57.37 in a neutral zone. The daily MACD confirms bullish momentum, and the price just broke its 20-day high — two short-term technical signals lining up. Today's volume is 2.23x average — well above normal activity, a sign of real interest. The analysts' average target price implies +50.7% upside — one of the score's strongest signals. Today it holds rank #19 in the Standard group on Smart Scanner's upside + relative volume ranking.
Price chart
IBRX
Price: $8.48 · RSI (14): 60.77 · Rel. volume: 0.43x · Breakout: No
- Current price: ($8.48) — solid white line — the latest available closing price.
- Target price: ($12.75) — dashed green line — average 12-month target price from analysts covering the stock.
- Quarter low: ($6.65) — dotted orange line — the lowest price over the last ~3 months, as a recent support reference.
You can zoom by dragging a rectangle over the chart, or with your mouse wheel. Double-click to reset the view.
What analysts say
IBRX
ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product…
- Buy 4
- Hold 0
- Sell 0
Average target price: $12.75 (+50.4% vs. current price) · range $12.0 – $15.0
Healthy Moderate Attention No data
Total market value of the company (price × shares outstanding).
P/E (trailing): compares the stock's price with its earnings per share over the last 12 months — how many times that earning is being paid for.
Not enough data to calculate it (no recent earnings or data unavailable).
P/E (forward): same as P/E, but using analysts' estimated earnings per share for the next year.
Same as P/E, using estimated future earnings.
PEG: the P/E divided by the expected earnings growth rate — relates how expensive the stock is to how fast it's expected to grow.
Not enough data (requires future growth estimates).
Debt/Equity: how much debt the company carries per dollar of shareholder equity — measures how leveraged the balance sheet is.
Not enough data.
Net margin: what percentage of each dollar of revenue ends up as net profit, after all costs.
Low margin: the business has little cushion if costs rise.
Dividend: what percentage of the stock's price is paid out in cash to shareholders each year.
Doesn't pay dividends: reinvests earnings into growth instead of distributing them.
Beta: how volatile the stock is compared to the overall market (S&P 500 = 1.0).
Less volatile than the overall market (S&P 500 = 1.0).
General reference ranges, do not vary by sector. Third-party data; may be incomplete. Not investment advice.
💰 Financial Statements (last 3 quarters)
💰 Financial Statements (last 3 quarters)
What this chart shows
- Japanese candlesticks: green when the period's close is higher than its open, red when it's lower.
- Volume: bars colored the same as the candle for that period.
- RSI (14): bottom line with reference levels at 70 (overbought) and 30 (oversold) — the same indicator the daily scanner uses.
- Dotted line on top: the high of the last 20 periods, the same reference the scanner uses to detect breakouts.
Third-party market data, for informational purposes. Not investment advice — read the disclaimer.